Brought to you by 
Plethora may get $28mm through arrangement with Paul Capital
17 Sep 2014
Executive Summary
Plethora Solutions Holdings PLC (urological conditions) has signed an agreement with Paul Capital Healthcare under which Plethora gets up to $28mm--$15mm cash up front, $10mm cash upon the first US sale of PSD502, and $3mm in equity--in exchange for revenue interest in Plethora's male health portfolio. The interest will mainly come from ErecAid (sold by the company's Timm Medical subsidiary for erectile dysfunction), PSD502 (Phase III for premature ejaculation and erectile dysfunction), and PSD510 (Phase III for erectile dysfunction).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
Deal Status
- Final
Deal Type
-
Financing
- Other
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Plethora may get $28mm through arrangement with Paul Capital
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice